Pharma Two B Ltd. Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson’s disease (PD) support P2B001 as a first line, once-daily ...

IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer’s Association International Conference.

5 th Annual Neuropsychiatric& Psychedelics Drug Development Summit Location: Boston, MA Titles:" The Preclinical Safety, Behavioral and Pharmacokinetics Properties of a Novel Prodrug of Psilocin ...

MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference ... Upcoming scientific conference participations. November 1-5, 2023 ...

Circle Pharma Announces Preclinical Data Poster Presentation of CID-078, a First-and-Only-in-Class Cyclin A/B RxL Inhibitor at the 2024 World Conference on Lung Cancer ...

Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer Oct. 24, 2023 8:00 AM ET Nuvectis Pharma, Inc. (NVCT) ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial ...

The poster presentations compare a novel prodrug of psilocin, MSP-1014, to psilocybin in preclinical studies evaluating safety, behavioral and pharmacokinetics properties of both psilocin prodrugs.

5th Annual Neuropsychiatric & Psychedelics Drug Development Summit in Boston, MA on October 31st Neuroscience 2022 by the Society of Neuroscience in San Diego, CA on November 13th TORONTO, Oct. 27 ...

TORONTO, Oct. 27, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized ...